Protalix Biotherapeutics ist eine kleine Biotech Firma in Israel. Sie erwarten eine Entscheidung von der FDA für ihr Medi gegen Morbus Gaucher. Die Chancen für eine Zulassung stehen gut.
Mean estimate : 11.71
Median estimate : 12.00
High estimate : 13.00
Low estimate : 10.00
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on the ProCellEx protein expression system (ProCellEx). Using the ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on the plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. The ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. The ProCellEx protein expression system is built on bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures.